Long-acting ORAI1 Blocker
Retinal Neovascular Disease (e.g., Diabetic Retinopathy, neovascular AMD)
Pre-clinicalActive
Key Facts
Indication
Retinal Neovascular Disease (e.g., Diabetic Retinopathy, neovascular AMD)
Phase
Pre-clinical
Status
Active
Company
About ForwardVue Pharma
ForwardVue Pharma is developing a novel, long-acting ORAI1 blocker designed to treat retinal neovascular diseases through a VEGF-independent mechanism. The lead candidate aims to achieve a dosing regimen of only 1-2 intravitreal injections per year, significantly reducing the treatment burden compared to current anti-VEGF standards. Founded and led by a practicing vitreoretinal surgeon-scientist, the company is in the preclinical stage with a patent-protected platform. Its approach targets pathways both upstream and downstream of VEGF, potentially offering a new therapeutic option for patients with inadequate responses to existing therapies.
View full company profile